ID

29253

Beskrivning

Comparison of Repaglinide and Gliclazide in Chinese Subjects With Type 2 Diabetes Never Received Oral Antidiabetic Drug Treatment; ODM derived from: https://clinicaltrials.gov/show/NCT01022762

Länk

https://clinicaltrials.gov/show/NCT01022762

Nyckelord

Versioner (1)
  1. 2018-03-12 2018-03-12 -
Rättsinnehavare

See clinicaltrials.gov

Uppladdad den

12 mars 2018

DOI

För en begäran logga in.

Licens

Creative Commons BY 4.0
Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Tillbaka till modellkommentarer
Itemgroup-kommentar för :

Item-kommentar för :

Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

Eligibility Diabetes NCT01022762

Engelsk

Eligibility Diabetes NCT01022762

1 Formulär  
  1. StudyEvent: Eligibility
    1. Eligibility Diabetes NCT01022762
Inclusion Criteria
Beskrivning

Inclusion Criteria

Alias
UMLS CUI
C1512693
type 2 diabetes
Beskrivning

Diabetes Mellitus, Non-Insulin-Dependent

Datatyp

boolean

Alias
UMLS CUI [1]
C0011860
oral anti-diabetic drug (oad) naïve (unsystematic oad treatment 6 months prior to this trial is allowed)
Beskrivning

Antidiabetics Oral naive | Antidiabetics Oral Irregular allowed

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0935929
UMLS CUI [1,2]
C1527415
UMLS CUI [1,3]
C0919936
UMLS CUI [2,1]
C0935929
UMLS CUI [2,2]
C1527415
UMLS CUI [2,3]
C0205271
UMLS CUI [2,4]
C0683607
insulin naïve (less than 1 week of daily use of insulin therapy before trial start is allowed)
Beskrivning

Insulin naive | Insulin regime short-term allowed

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0021641
UMLS CUI [1,2]
C0919936
UMLS CUI [2,1]
C0557978
UMLS CUI [2,2]
C0443303
UMLS CUI [2,3]
C0683607
lipid-lowing agent naïve
Beskrivning

Hypoglycemic Agents naive

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0020616
UMLS CUI [1,2]
C0919936
hba1c: 6.5-8.5%
Beskrivning

Glucohemoglobin measurement

Datatyp

boolean

Alias
UMLS CUI [1]
C0202054
fasting glucose: 6.1-13.0 mmol/l (110-234 mg/dl)
Beskrivning

Glucose measurement, fasting

Datatyp

boolean

Alias
UMLS CUI [1]
C0202045
body mass index (bmi): 20-35 kg/m^2
Beskrivning

Body mass index

Datatyp

boolean

Alias
UMLS CUI [1]
C1305855
be able and willing to perform self-monitored plasma glucose (smpg)
Beskrivning

Plasma Glucose Self Monitoring Able | Plasma Glucose Self Monitoring Willing

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0202042
UMLS CUI [1,2]
C0588436
UMLS CUI [1,3]
C0085732
UMLS CUI [2,1]
C0202042
UMLS CUI [2,2]
C0588436
UMLS CUI [2,3]
C0600109
be able and willing to eat 3 main meals per day
Beskrivning

Meal Main Quantity per day

Datatyp

boolean

Alias
UMLS CUI [1,1]
C1998602
UMLS CUI [1,2]
C1542147
UMLS CUI [1,3]
C1265611
UMLS CUI [1,4]
C0439505
only applicable to subjects who will participate in the subgroup study: be able and willing to perform and complete ivgtt (intravenous glucose tolerance test) at additional visits
Beskrivning

Subgroup Clinical Trial | Intravenous Glucose Tolerance Test Completion

Datatyp

boolean

Alias
UMLS CUI [1,1]
C1515021
UMLS CUI [1,2]
C0008976
UMLS CUI [2,1]
C0021911
UMLS CUI [2,2]
C0205197
Exclusion Criteria
Beskrivning

Exclusion Criteria

Alias
UMLS CUI
C0680251
known or suspected allergy to repaglinide, gliclazide, or related products (for example sulfonamide or other sulphonylureas (sus)), or any of the excipients in the study drugs
Beskrivning

Hypersensitivity repaglinide | Hypersensitivity Suspected repaglinide | Gliclazide allergy | Hypersensitivity Suspected Gliclazide | Hypersensitivity Pharmaceutical Preparations Related | Hypersensitivity Suspected Pharmaceutical Preparations Related | Hypersensitivity Sulfonamides | Hypersensitivity Suspected Sulfonamides | Hypersensitivity Sulfonylurea | Hypersensitivity Suspected Sulfonylurea | Hypersensitivity Investigational New Drugs Excipient | Hypersensitivity Suspected Investigational New Drugs Excipient

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0246689
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0750491
UMLS CUI [2,3]
C0246689
UMLS CUI [3]
C0571641
UMLS CUI [4,1]
C0020517
UMLS CUI [4,2]
C0750491
UMLS CUI [4,3]
C0017631
UMLS CUI [5,1]
C0020517
UMLS CUI [5,2]
C0013227
UMLS CUI [5,3]
C0439849
UMLS CUI [6,1]
C0020517
UMLS CUI [6,2]
C0750491
UMLS CUI [6,3]
C0013227
UMLS CUI [6,4]
C0439849
UMLS CUI [7,1]
C0020517
UMLS CUI [7,2]
C0038760
UMLS CUI [8,1]
C0020517
UMLS CUI [8,2]
C0750491
UMLS CUI [8,3]
C0038760
UMLS CUI [9,1]
C0020517
UMLS CUI [9,2]
C0038766
UMLS CUI [10,1]
C0020517
UMLS CUI [10,2]
C0750491
UMLS CUI [10,3]
C0038766
UMLS CUI [11,1]
C0020517
UMLS CUI [11,2]
C0013230
UMLS CUI [11,3]
C0015237
UMLS CUI [12,1]
C0020517
UMLS CUI [12,2]
C0750491
UMLS CUI [12,3]
C0013230
UMLS CUI [12,4]
C0015237
previous participation in this study
Beskrivning

Study Subject Participation Status

Datatyp

boolean

Alias
UMLS CUI [1]
C2348568
participation in a study of another investigational drug within 1 month prior to study start
Beskrivning

Study Subject Participation Status | Investigational New Drugs

Datatyp

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C0013230
Tillbaka till toppen

Similar models

Eligibility Diabetes NCT01022762

1 Formulär
  1. StudyEvent: Eligibility
    1. Eligibility Diabetes NCT01022762
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
C1512693 (UMLS CUI)
Diabetes Mellitus, Non-Insulin-Dependent
Item
type 2 diabetes
boolean
C0011860 (UMLS CUI [1])
Antidiabetics Oral naive | Antidiabetics Oral Irregular allowed
Item
oral anti-diabetic drug (oad) naïve (unsystematic oad treatment 6 months prior to this trial is allowed)
boolean
C0935929 (UMLS CUI [1,1])
C1527415 (UMLS CUI [1,2])
C0919936 (UMLS CUI [1,3])
C0935929 (UMLS CUI [2,1])
C1527415 (UMLS CUI [2,2])
C0205271 (UMLS CUI [2,3])
C0683607 (UMLS CUI [2,4])
Insulin naive | Insulin regime short-term allowed
Item
insulin naïve (less than 1 week of daily use of insulin therapy before trial start is allowed)
boolean
C0021641 (UMLS CUI [1,1])
C0919936 (UMLS CUI [1,2])
C0557978 (UMLS CUI [2,1])
C0443303 (UMLS CUI [2,2])
C0683607 (UMLS CUI [2,3])
Hypoglycemic Agents naive
Item
lipid-lowing agent naïve
boolean
C0020616 (UMLS CUI [1,1])
C0919936 (UMLS CUI [1,2])
Glucohemoglobin measurement
Item
hba1c: 6.5-8.5%
boolean
C0202054 (UMLS CUI [1])
Glucose measurement, fasting
Item
fasting glucose: 6.1-13.0 mmol/l (110-234 mg/dl)
boolean
C0202045 (UMLS CUI [1])
Body mass index
Item
body mass index (bmi): 20-35 kg/m^2
boolean
C1305855 (UMLS CUI [1])
Plasma Glucose Self Monitoring Able | Plasma Glucose Self Monitoring Willing
Item
be able and willing to perform self-monitored plasma glucose (smpg)
boolean
C0202042 (UMLS CUI [1,1])
C0588436 (UMLS CUI [1,2])
C0085732 (UMLS CUI [1,3])
C0202042 (UMLS CUI [2,1])
C0588436 (UMLS CUI [2,2])
C0600109 (UMLS CUI [2,3])
Meal Main Quantity per day
Item
be able and willing to eat 3 main meals per day
boolean
C1998602 (UMLS CUI [1,1])
C1542147 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C0439505 (UMLS CUI [1,4])
Subgroup Clinical Trial | Intravenous Glucose Tolerance Test Completion
Item
only applicable to subjects who will participate in the subgroup study: be able and willing to perform and complete ivgtt (intravenous glucose tolerance test) at additional visits
boolean
C1515021 (UMLS CUI [1,1])
C0008976 (UMLS CUI [1,2])
C0021911 (UMLS CUI [2,1])
C0205197 (UMLS CUI [2,2])
Item Group
C0680251 (UMLS CUI)
Hypersensitivity repaglinide | Hypersensitivity Suspected repaglinide | Gliclazide allergy | Hypersensitivity Suspected Gliclazide | Hypersensitivity Pharmaceutical Preparations Related | Hypersensitivity Suspected Pharmaceutical Preparations Related | Hypersensitivity Sulfonamides | Hypersensitivity Suspected Sulfonamides | Hypersensitivity Sulfonylurea | Hypersensitivity Suspected Sulfonylurea | Hypersensitivity Investigational New Drugs Excipient | Hypersensitivity Suspected Investigational New Drugs Excipient
Item
known or suspected allergy to repaglinide, gliclazide, or related products (for example sulfonamide or other sulphonylureas (sus)), or any of the excipients in the study drugs
boolean
C0020517 (UMLS CUI [1,1])
C0246689 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0750491 (UMLS CUI [2,2])
C0246689 (UMLS CUI [2,3])
C0571641 (UMLS CUI [3])
C0020517 (UMLS CUI [4,1])
C0750491 (UMLS CUI [4,2])
C0017631 (UMLS CUI [4,3])
C0020517 (UMLS CUI [5,1])
C0013227 (UMLS CUI [5,2])
C0439849 (UMLS CUI [5,3])
C0020517 (UMLS CUI [6,1])
C0750491 (UMLS CUI [6,2])
C0013227 (UMLS CUI [6,3])
C0439849 (UMLS CUI [6,4])
C0020517 (UMLS CUI [7,1])
C0038760 (UMLS CUI [7,2])
C0020517 (UMLS CUI [8,1])
C0750491 (UMLS CUI [8,2])
C0038760 (UMLS CUI [8,3])
C0020517 (UMLS CUI [9,1])
C0038766 (UMLS CUI [9,2])
C0020517 (UMLS CUI [10,1])
C0750491 (UMLS CUI [10,2])
C0038766 (UMLS CUI [10,3])
C0020517 (UMLS CUI [11,1])
C0013230 (UMLS CUI [11,2])
C0015237 (UMLS CUI [11,3])
C0020517 (UMLS CUI [12,1])
C0750491 (UMLS CUI [12,2])
C0013230 (UMLS CUI [12,3])
C0015237 (UMLS CUI [12,4])
Study Subject Participation Status
Item
previous participation in this study
boolean
C2348568 (UMLS CUI [1])
Study Subject Participation Status | Investigational New Drugs
Item
participation in a study of another investigational drug within 1 month prior to study start
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
Tillbaka till toppen 

Kontakt

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial